Aerovate Therapeutics (NASDAQ:AVTE - Get Free Report) is projected to release its earnings data before the market opens on Monday, March 24th. Analysts expect Aerovate Therapeutics to post earnings of ($0.40) per share for the quarter.
Aerovate Therapeutics Stock Performance
Shares of AVTE traded down $0.03 during trading hours on Thursday, reaching $2.50. The stock had a trading volume of 21,574 shares, compared to its average volume of 578,308. Aerovate Therapeutics has a 12 month low of $1.25 and a 12 month high of $32.42. The stock has a market capitalization of $72.04 million, a PE ratio of -0.84 and a beta of 1.01. The company's 50-day moving average is $2.49 and its two-hundred day moving average is $2.41.
Aerovate Therapeutics Company Profile
(
Get Free Report)
Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.
Featured Articles
Before you consider Aerovate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aerovate Therapeutics wasn't on the list.
While Aerovate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
